Real-world study of a bivalent mRNA vaccine booster in preventing severe COVID-19 outcomes in non-hospitalized subjects

A large real-world study demonstrates much lower rates of hospitalization and mortality due to COVID-19 for recipients of the Pfizer-BioNTech bivalent mRNA COVID-19 booster vaccine than for non-recipients, amongst non-hospitalized participants over the age of 65. A team of researchers in Israel has recently conducted one of the first studies to evaluate the real-world effectiveness of the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine as a booster for preventing severe COVID-19 outcomes in non-hospitalized individuals over 65. Their findings have been published as a preprint research paper on Preprints with the Lancet*, which has not been peer reviewed and reports preliminary findings....